Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma

Published:2021-02-15 Issue:4 Volume:21 Page:455-463
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Salles Gilles¹,Długosz-Danecka Monika²,Ghesquières Hervé³,Jurczak Wojciech²

Affiliation:

1. Lymphoma Service, Memorial Sloan Kettering Cancer Center, NY, USA

2. Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland

3. Hématologie, Hospices Civils De Lyon and Université De Lyon, Lyon, France

Funder

MorphoSys AG

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2021.1884677

Reference50 articles.

1. Global patterns and trends in the incidence of non-Hodgkin lymphoma

2. My Treatment Approach to Patients With Diffuse Large B-Cell Lymphoma

3. Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975–2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020

4. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

5. Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma;Human Vaccines & Immunotherapeutics;2024-02

2. Flow cytometry interference in patients treated with tafasitamab: Unraveling the diagnostic maze;HemaSphere;2024-01

3. Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023;Seminars in Hematology;2023-12

4. Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models;Leukemia & Lymphoma;2023-08-07

5. Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging;Biomedicines;2023-07-24